Cash and Cash Equivalents, at Carrying Value of Zenas BioPharma, Inc. from 30 Sep 2023 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Summary
Zenas BioPharma, Inc. quarterly Cash and Cash Equivalents, at Carrying Value in USD history and change rate from 30 Sep 2023 to 31 Dec 2025.
  • Zenas BioPharma, Inc. Cash and Cash Equivalents, at Carrying Value for the quarter ending 31 Dec 2025 was $110,641,000, a 65% decline year-over-year.
Source SEC data
View on sec.gov
Cash and Cash Equivalents, at Carrying Value, Quarterly (USD)
Cash and Cash Equivalents, at Carrying Value, YoY Quarterly Change (%)

Zenas BioPharma, Inc. Quarterly Cash and Cash Equivalents, at Carrying Value (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $110,641,000 -$209,101,000 -65% 31 Dec 2025 10-K 16 Mar 2026 2025 FY
Q3 2025 $115,565,000 -$244,473,000 -68% 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $44,006,000 -$139,924,000 -76% 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $196,554,000 +$159,400,000 +429% 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $319,742,000 +$262,885,000 +462% 31 Dec 2024 10-K 16 Mar 2026 2025 FY
Q3 2024 $360,038,000 +$287,727,000 +398% 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $183,930,000 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $37,154,000 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $56,857,000 31 Dec 2023 10-K 11 Mar 2025 2024 FY
Q3 2023 $72,311,000 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.